CRISPR biotech Intellia leases a big R&D hub in Cambridge, MA

Damian Garde Intellia Therapeutics, a Novartis-backed biotech working on gene-editing technology, leased a sizable research space in the hotbed of Cambridge, MA. FierceBiotech News

AbbVie and Roche’s cancer drug snags another ‘breakthrough’ tag

Damian Garde AbbVie and Roche's cancer drug venetoclax, awaiting FDA approval, picked up another breakthrough therapy nod from the agency for its potential as part of a combination ...

Money-back guarantees on cancer drugs are real in Italy, and the world is watching

Tracy Staton One country is ahead of the curve in striking pay-for-performance deals on cancer drugs–and, more importantly, collecting the cash when treatments don't hit their ...

Biotech rehearses its ‘difficult’ second album at #JPM16

Damian Garde The two most commonly watched indexes of biotech stocks have each fallen more than 35% from their July peaks, battered down by a pervasive sense that the frothy days of ...

UPDATED: Sarepta shares crash on a harsh FDA review of Duchenne’s drug

John Carroll Sarepta's quest to gain an accelerated approval for eteplirsen was subjected to some harsh scrutiny by regulators at the FDA. And the insiders concluded that much of ...

FTC stats show pharma backing off pay-for-delay deals after SCOTUS ruling

Tracy Staton For years, the Federal Trade Commission lamented the ever-growing number of pay-for-delay patent settlements–three in 2005, 14 in 2007, up to a record 40 in 2012–and ...

Federal judge declines to toss Paxil suicide case, setting GSK up for September trial

Tracy Staton GlaxoSmithKline will have to go to court to fight claims that a generic version of its Paxil antidepressant triggered an Illinois man's suicide. U.S. ...

Cardiorentis raises $60M as PhIII heart failure trial nears completion

Nick Paul Taylor Cardiorentis has raised CHF 60 million ($ 60 million). The investment bolsters the biotech's bank balance at a time when it is nearing the end of a Phase III trial ...

New Bayer site to make traditional Chinese and Western consumer health meds

Eric Palmer Bayer snapped up China's Dihon in 2014 with the idea of combining Dihon's traditional Chinese medicines with Bayer's Western OTC products in a major consumer ...

CEO Frazier expects Merck to be player in hep C market, M&A this year

Eric Palmer Merck & Co.'s CEO Kenneth Frazier expects his company to be a player in that lucrative hepatitis C market again with the anticipated approval this month of its hep ...

Aegerion names Mary Szela CEO to replace controversial, and overly talkative, Marc Beer

Eric Palmer Aegerion Pharmaceuticals, which dumped controversial CEO Marc Beer last summer, has named industry veteran Mary Szela as its new chief executive. FiercePharma News

GSK whistleblower claims to have been fired after emailing CEO about Nicoderm concerns

Eric Palmer GlaxoSmithKline's Nicoderm products are among the leaders in helping smokers kick their habits. But a former employee says the study that showed their edge over ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS